PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $95.00

PTC Therapeutics (NASDAQ:PTCT) had its price objective upped by Wells Fargo & Company from $86.00 to $95.00 in a research report released on Friday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biopharmaceutical company’s stock.

Several other research analysts have also commented on PTCT. Raymond James Financial began coverage on shares of PTC Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $108.00 price objective for the company. Morgan Stanley raised their price objective on shares of PTC Therapeutics from $90.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, February 23rd. Bank of America lowered their price objective on shares of PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Barclays reissued an “overweight” rating and issued a $120.00 price objective on shares of PTC Therapeutics in a research note on Monday, February 23rd. Finally, Truist Financial raised shares of PTC Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, PTC Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $88.36.

PTC Therapeutics Stock Performance

NASDAQ PTCT opened at $73.69 on Friday. The firm has a 50 day simple moving average of $67.69 and a 200-day simple moving average of $72.07. PTC Therapeutics has a one year low of $43.17 and a one year high of $87.50. The firm has a market cap of $6.11 billion, a price-to-earnings ratio of -31.63 and a beta of 0.53.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.42. PTC Therapeutics had a negative net margin of 22.58% and a negative return on equity of 362.45%. The business had revenue of $272.55 million during the quarter, compared to analyst estimates of $217.42 million. During the same quarter last year, the firm posted $10.04 earnings per share. The business’s revenue for the quarter was up 43.5% compared to the same quarter last year. Equities analysts predict that PTC Therapeutics will post -1.09 EPS for the current fiscal year.

Insider Transactions at PTC Therapeutics

In related news, insider Neil Gregory Almstead sold 52,003 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $69.04, for a total value of $3,590,287.12. Following the sale, the insider owned 60,137 shares of the company’s stock, valued at $4,151,858.48. This trade represents a 46.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Lee Scott Golden sold 829 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $67.99, for a total transaction of $56,363.71. Following the completion of the sale, the executive vice president directly owned 79,115 shares in the company, valued at approximately $5,379,028.85. This trade represents a 1.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 126,492 shares of company stock valued at $8,634,621 over the last quarter. Insiders own 5.50% of the company’s stock.

Institutional Trading of PTC Therapeutics

Several hedge funds have recently added to or reduced their stakes in PTCT. UMB Bank n.a. acquired a new stake in PTC Therapeutics in the fourth quarter valued at approximately $26,000. Smartleaf Asset Management LLC raised its holdings in PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 236 shares in the last quarter. Optiver Holding B.V. raised its holdings in PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 249 shares in the last quarter. Comerica Bank raised its holdings in PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares in the last quarter. Finally, Salomon & Ludwin LLC acquired a new stake in PTC Therapeutics during the fourth quarter worth approximately $41,000.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported Q1 revenue of $273 million and EPS of -$0.03, beating Wall Street estimates on both the top and bottom line. Revenue was up 43.5% year over year, and the company said its updated results support a higher full-year 2026 outlook. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company raised FY 2026 revenue guidance to $1.1 billion-$1.2 billion, above the market’s prior expectation of about $1.0 billion, signaling stronger commercial momentum. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
• Positive Sentiment: Wells Fargo lifted its price target on PTCT from $86 to $95 and kept an Overweight rating, suggesting further upside if execution continues. Benzinga report on Wells Fargo price target increase
• Neutral Sentiment: Royal Bank of Canada raised its price target from $81 to $82 while maintaining a Sector Perform rating, indicating a more measured view than Wells Fargo despite still acknowledging some upside. Benzinga report on RBC price target increase
• Neutral Sentiment: Management also highlighted progress in its pipeline and programs, including Sephience launch growth and positive interim data for votoplam, which may support longer-term sentiment but is less immediately impactful than the earnings beat. PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.